Kaitlin Matthes, PA
Medical · Lincoln, NENPI 1306109491
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,532 of the $97,775 with a category attached, or 75.2%. 20 manufacturers reported payments, led by Galderma Laboratories, L.p. at 46.7% of the total. Reporting peaked in 2023 at $53,911 and has fallen 54.4% since, to $24,557 in 2024. Among medical clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 644 payments — averaging $151.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$46K
- Sanofi$36K
- Regeneron Healthcare Solutions, Inc.$10K
- AbbVie$2K
- Lilly USA, LLC$873
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$814
- plus $3K from 14 others
What the payments were for
- Consulting fees$1,0941%
- Speaking & faculty fees$73,53275%
- Travel & lodging$10,58411%
- Food & beverage$12,00512%
- Education$5611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 115 | $45,632 |
| Sanofi | 73 | $35,694 |
| Regeneron Healthcare Solutions, Inc. | 99 | $9,721 |
| AbbVie(2 entities) | 113 | $1,691 |
| Lilly USA, LLC | 62 | $873 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 16 | $814 |
| Sun Pharmaceutical Industries Inc. | 45 | $806 |
| UCB, Inc. | 25 | $556 |
| Incyte Corporation | 22 | $442 |
| Novartis | 25 | $312 |
| E.r. Squibb & Sons, L.L.C. | 15 | $255 |
| Johnson & Johnson | 8 | $191 |
| Dermavant Sciences, Inc. | 3 | $182 |
| Janssen Scientific Affairs, LLC | 2 | $160 |
| LEO Pharma Inc. | 5 | $130 |
| Pfizer | 6 | $88 |
| Regeneron | 3 | $86 |
| Amgen | 4 | $79 |
| Arcutis Biotherapeutics, Inc. | 2 | $37 |
| VYNE Pharmaceuticals Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,775 in reported general payments places this provider in the 95th percentile of 216 medical providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 16 | $62,873 |
| Metronidazole | 11 | $495 |
| Ketoconazole | 18 | $325 |
| Triamcinolone Acetonide | 22 | $177 |
Paid to pharmacies, not to this prescriber.
Other medical in Lincoln
- Michelle SitzmanLincoln$206K
- Jay ArthurLincoln$8K
- Emma EdwardsLincoln$8K
- Erin HeggeLincoln$7K
- Christine TrombinoLincoln$5K
- Samantha PedersonLincoln$5K
- Sheri JohnsonLincoln$5K
- Kerri OttoLincoln$5K
- Mason BeelLincoln$4K
- Erin ZimmermanLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.